Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024

Europe biosimilar insulin glargine and lispro market is projected to reach $ 1.9 billion by 2024 owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedentary lifestyle. United Kingdom ranks among the top 5 countries with the highest rate of Type 1 diabetes in children. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of biosimilar insulin glargine and lispro market in the forthcoming years. The insulin analogue retains its glucose lowering property for 24 hours with just one injection. Due to this property, the insulin analogue is preferred for maintaining the basal insulin level throughout the day, thereby aiding the market growth. Growing concern regarding the cost of insulin treatment is surging the demand for biosimilar insulin glargine and lispro that have the potential to reduce diabetes treatment costs, which is anticipated to boost the growth of market in the next 5 years. Moreover, ageing population and changing eating habits are further giving healthy push to Europe biosimilar insulin glargine and lispro market.
On the basis of end users, the biosimilar insulin glargine and lispro market is bifurcated into Type 1 Diabetes and Type 2 Diabetes. Among them, Type 1 Diabetes dominated the market with the largest market share until 2018 and is anticipated to maintain its position during the forecast period as well. The reason being, Type 1 diabetes is categorized as an autoimmune disease, therefore the body doesnt produce any insulin. The only way to treat this disorder is getting oneself injected with insulin and getting the blood glucose levels regulated. Thereby, treatment of Type 1 diabetes generates maximum demand for insulin glargine and lispro in the region. With the higher adoption of sedentary lifestyle, especially in the growing economies people are facing difficulty in controlling Type 2 diabetes. Therefore, the utilization of biosimilar insulin glargine and lispro to treat Type 2 diabetes is expected to witness some growth during the forecast period.
Some of the players in Europe biosimilar insulin glargine and lispro are Sanofi, Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk, Sandoz-Gan Lee, etc. The key players in the market are using strategies such as launch of new products, mergers and acquisitions to increase their customer base and expand their share in the market.
Years considered for this report:
Historical Years: 2014-2017
Base Year: 2018
Estimated Year: 2019
Forecast Period: 20202024
Objective of the Study:
To analyze and forecast the market size of Europe biosimilar insulin glargine and lispro market.
To forecast Europe biosimilar insulin glargine and lispro market based on end user, , and regional distribution.
To identify drivers and challenges for Europe biosimilar insulin glargine and lispro market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Europe biosimilar insulin glargine and lispro market.
To conduct the pricing analysis for Europe biosimilar insulin glargine and lispro market.
To identify and analyze the profile of leading players operating in Europe biosimilar insulin glargine and lispro market.
It performed both primary as well as exhaustive secondary research for this study. Initially, It sourced a list of biosimilar insulin glargine and lispro manufacturers across the region. Subsequently, It conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, It could include the suppliers which could not be identified due to the limitations of secondary research. It analyzed the product types, application types and presence of all major biosimilar insulin glargine and lispro manufacturers across the region.
It calculated Europe biosimilar insulin glargine and lispro market size by using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. It sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by It.
Key Target Audience:
Biosimilar insulin glargine and lispro manufacturers, suppliers, distributors and other stakeholders
Government bodies such as regulating authorities and policy makers
Organizations, forums and alliances related to biosimilar insulin glargine and lispro market
Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers and partners, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, Europe biosimilar insulin glargine & lispro market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Market, By End User:
o Type 1 Diabetes
o Type 2 Diabetes
Market, By Country:
o Germany
o United Kingdom
o France
o Italy
o Spain
o Russia
o Turkey
o Poland
o The Netherlands
o Austria
o Rest of Europe

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in biosimilar insulin glargine & lispro market.
Available Customizations:
With the given market data, It offers customizations according to a companys specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Profit Margin Analysis
Profit margin analysis in case of direct and indirect sales channel.


1.Product Overview
2.Research Methodology
3.Executive Summary
4.Voice of Customer
4.1.Brand Awareness
4.2.Factors Influencing Purchase Decision
4.3.Unmet Needs & Challenges
5.Global Biosimilar Insulin Market Overview
6.Europe Biosimilar Insulin Glargine & Lispro Market Outlook
6.1.Market Size & Forecast, (2014-2024)
6.1.1.By Value (USD Million) & Volume (Million Units)
6.2.Market Share & Forecast (2014-2024)
6.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.2.2.By Country (United Kingdom, Germany, France, Spain, Italy, Russia, Netherlands, Poland, Turkey & Rest of Europe)
6.2.3.By Company (2018)
6.3.Market Attractiveness Index
6.4.Competition Outlook
6.4.1.Major Biosimilar Insulin Glargine & Lispro Suppliers with products registered and sold
6.5.Country Analysis
6.5.1.Germany Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.1.1.Market Size & Forecast
6.5.1.1.1.By Value & Volume
6.5.1.2.Market Share & Forecast
6.5.1.2.1.By End User
6.5.2.United Kingdom Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.2.1.Market Size & Forecast
6.5.2.1.1.By Value & Volume
6.5.2.2.Market Share & Forecast
6.5.2.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.3.France Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.3.1.Market Size & Forecast
6.5.3.1.1.By Value & Volume
6.5.3.2.Market Share & Forecast
6.5.3.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.4.Italy Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.4.1.Market Size & Forecast
6.5.4.1.1.By Value & Volume
6.5.4.2.Market Share & Forecast
6.5.4.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.5.Spain Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.5.1.Market Size & Forecast
6.5.5.1.1.By Value & Volume
6.5.5.2.Market Share & Forecast
6.5.5.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.6.Russia Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.6.1.Market Size & Forecast
6.5.6.1.1.By Value & Volume
6.5.6.2.Market Share & Forecast
6.5.6.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.7.Turkey Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.7.1.Market Size & Forecast
6.5.7.1.1.By Value & Volume
6.5.7.2.Market Share & Forecast
6.5.7.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.8.Poland Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.8.1.Market Size & Forecast
6.5.8.1.1.By Value & Volume
6.5.8.2.Market Share & Forecast
6.5.8.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.9.The Netherlands Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.9.1.Market Size & Forecast
6.5.9.1.1.By Value & Volume
6.5.9.2.Market Share & Forecast
6.5.9.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.10.Austria Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.10.1.Market Size & Forecast
6.5.10.1.1.By Value & Volume
6.5.10.2.Market Share & Forecast
6.5.10.2.1.By End User (Type 1 Diabetes, Type 2 Diabetes)
7.Market Dynamics
7.1.Drivers
7.2.Challenges
8.Market Trends & Developments
9.Porters Five Forces Analysis
9.1.Bargaining Power of Suppliers
9.2.Bargaining Power of Consumers
9.3.Threat of New Suppliers
9.4.Threat of Substitute
9.5.Competitive Rivalry
10.Competitive Landscape
10.1.Competition Outlook
10.2.Company Profiles
10.2.1.Basic Financial Details (Revenue, Gross Profit, Net Profit)
10.2.2.Sales Value and Volume of Product of Interest
10.2.3.Key Strategies
10.2.3.1.New Products Launches
10.2.3.2.Product Development Plan
10.2.3.3.Expansion Plan
10.2.4.Supply Chain Analysis
10.2.5.Business Distribution
10.2.6.SWOT Analysis
11.Timelines from Drug Development to Commercial Launch
12.Strategic Recommendations

List Of Figures

Figure 1: Europe Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F (USD Million)
Figure 2: Europe Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 4: Europe Diabetic Population Share, 2017
Figure 3: Germany Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 4: Germany Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 5: United Kingdom Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 6: United Kingdom Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 7: France Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 8: France Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 9: Italy Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 10: Italy Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 11: Spain Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 12: Spain Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 13: Russia Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 14: Russia Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 15: Turkey Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 16: Turkey Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 17: Poland Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 18: Poland Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 19: The Netherlands Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 20: The Netherlands Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 21: Austria Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 22: Austria Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 23: Europe Biosimilar Insulin Glargine and Lispro Pricing Analysis, 2014-2024F

2020 Europe Virology and Bacteriology Market for over 100 Tests: France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation, Opportunities

This new report is a five-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key trends in major

USD 19700 View Report

2020 Global Virology and Bacteriology Market for over 100 Tests: US, Europe, Japan--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation, Opportunities

This new report is a seven-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key trends in the U.S.,

USD 28500 View Report

Asia Pacific Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes), By Country (Japan, China, India, South Korea, Bangladesh, Pakistan), Competition, Forecast & Opportunities, 2024

Biosimilar is a biological product which is similar to the reference product, already approved by authorities and marketed by companies other than the patent holder company. Insulin is a hormone

USD 3950 View Report

Europe Biosimilars Insulin Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Biosimilars Insulin market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by the

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available